Plasma Endothelin Immunoreactivity in Liver Disease and the Hepatorenal Syndrome

New England Journal of Medicine

Volumn 327, Issue 25, 1992, Pages 1774-1778

  Moore, Kevin ^a   Wendon, Julia ^b   Frazer, Marshall ^c   Karani, John ^b   Williams, Roger ^b   Badr, Kamal ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN 3;

ARTICLE; CONTROLLED STUDY; FEMALE; HEPATORENAL SYNDROME; HUMAN; IMMUNOREACTIVITY; KIDNEY BLOOD FLOW; KIDNEY FAILURE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

CHRONIC DISEASE; ENDOTHELINS; FEMALE; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; LIVER DISEASES; MALE; RADIOIMMUNOASSAY; SUPPORT, NON-U.S. GOV'T;

EID: 0026490970     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199212173272502     Document Type: Article

References (26)

1. Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis: the role of active vasoconstriction. Am J Med 1970; 49: 175–85.
2. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151–7.
3. Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional nemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97: 1304–12.
4. Arroyo V, Planas R, Gaya J, et al. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis: relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 1983; 13: 271–8.
5. Wilkinson SP, Smith IK, Williams R. Renal failure in liver disease: role of endotoxins and renin-angiotensin system. In: Epstein M, ed. The kidney in liver disease. New York: Elsevier, 1978:113–20.
6. Zipser RD, Radvan GH, Kronborg U, Duke R, Little TE. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 1983; 84: 697–703.
7. Rimola A, Gines P, Arroyo V, et al. Urinary excretion of 6-keto prostaglandin F1α, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites: relationship to functional renal failure (hepatorenal syndrome). J Hepatol 1986; 3: 111–7.
8. Epstein M, Lifschitz M. Renal eicosanoids as determinants of renal function in liver disease. Hepatology 1987; 7: 1359–67.
9. Moore K, Ward PS, Taylor GW, Williams R. Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenterology 1991; 100: 1069–77.
10. Moore KP, Taylor GW, Maltby NH, et al. Increased production of cysteinyl leukotrienes in hepatorenal syndrome. J Hepatol 1990; 11: 263–71.
11. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney: elucidation of signal transduction pathways. J Clin Invest 1989; 83: 336–42.
12. Pemow J, Boutier JF, Franco-Cereceda A, Lacroix JS, Matran R, Lundberg JM. Potent selective vasoconstrictor effects of endothelin in the pig kidney in vivo. Acta Physiol Scand 1988; 134: 573–4.
13. Brenner BM, Troy JL, Ballermann BJ. Endothelium-dependent vascular responses: mediators and mechanisms. J Clin Invest 1989; 84: 1373–8.
14. Munger KA, Badr KF. Endothelin: new insights into cellular mechanisms and renal actions In: Goldfarb S, Ziyadeh FN, eds. Hormones, autacoids, and the kidney. Vol. 23 of Contemporary issues in nephrology. New York: Churchill Livingstone, 1991:297–314.
15. Kon V, Badr KF. Biological actions and pathophysiologic significance of endothelin in the kidney. Kidney Int 1991; 40: 1–12.
16. Hirata Y, Yoshimi H, Takata S, et al. Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. Biochem Biophys Res Commun 1988; 154: 868–75.
17. Tomita K, Ujiie K, Nakanishi T, et al. Plasma endothelin levels in patients with acute renal failure. N Engl J Med 1989; 321: 1127.
18. Clarke JG, Benjamin N, Larkin SW, Webb DJ, Davies GJ, Maseri A. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol 1989; 257: H2033–H2035.
19. Hemsen A. Biochemical and functional characterization of endothelin peptides with special reference to vascular effects. Acta Physiol Scand Suppl 1991; 602: 1–61.
20. Badr KF, Munger KA, Sugiura M, Snajdar RM, Schwartzberg M, Inagami T. High and low affinity binding sites for endothelin in cultured rat glomerular mesangial cells. Biochem Biophys Res Commun 1989; 161: 766–81.
21. Emori T, Hirata Y, Kanno K, et al. Endothelin-3 stimulates production of endothelium-derived nitric oxide via phosphoinositide breakdown. Biochem Biophys Res Commun 1991; 174: 228–35.
22. Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest 1977; 37: 635–42.
23. Moreau R, Braillon A, Roulot D, et al. Hypoxie tissulaire et insuffisance hépatocellulaire chez les maladies atteints de cirrhose. Gastroenterol Clin Biol 1989; 13: 978–83.
24. Boulanger CM, Tanner FC, Bea M-L, Hahn AWA, Werner A, Lüscher TF. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 1992; 70: 1191–7.
25. Pernow J, Hemsen A, Hallen A, Lundberg JM. Release of endothelin-like immunoreactivity in relation to neuropeptide Y and catecholamines during endotoxin shock and asphyxia in the pig. Acta Physiol Scand 1990; 140: 311–22.
26. Kaufmann H, Oribe E, Oliver JA. Plasma endothelin during upright tilt: relevance for orthostatic hypotension? Lancet 1991; 338: 1542–5.